Benchmark Begins Coverage on Kamada (NASDAQ:KMDA)

Investment analysts at Benchmark started coverage on shares of Kamada (NASDAQ:KMDA) in a report released on Friday, Marketbeat Ratings reports. The firm set a “buy” rating and a $15.00 price target on the biotechnology company’s stock. Benchmark’s price objective indicates a potential upside of 125.56% from the stock’s current price.

Several other research firms have also recently weighed in on KMDA. StockNews.com raised Kamada from a “buy” rating to a “strong-buy” rating in a research report on Thursday, March 13th. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price target on shares of Kamada in a research note on Thursday, March 6th.

Kamada Trading Down 0.4 %

Shares of NASDAQ KMDA opened at $6.65 on Friday. The firm has a fifty day simple moving average of $7.21 and a two-hundred day simple moving average of $6.24. Kamada has a 12 month low of $4.74 and a 12 month high of $9.16. The firm has a market capitalization of $382.24 million, a PE ratio of 23.75, a price-to-earnings-growth ratio of 0.97 and a beta of 0.97.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. bought a new stake in Kamada in the fourth quarter worth $67,000. Public Employees Retirement System of Ohio bought a new position in Kamada in the 3rd quarter worth about $77,000. NewEdge Advisors LLC grew its position in Kamada by 54.2% during the 4th quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company’s stock valued at $143,000 after purchasing an additional 8,260 shares during the last quarter. Geode Capital Management LLC grew its position in Kamada by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company’s stock valued at $178,000 after purchasing an additional 1,549 shares during the last quarter. Finally, Aristides Capital LLC raised its holdings in Kamada by 12.1% in the fourth quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company’s stock worth $387,000 after buying an additional 6,850 shares during the last quarter. Institutional investors own 20.38% of the company’s stock.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.